Literature DB >> 28470870

A Multicenter Study on Long-Term Outcomes After Lung Transplantation Comparing Donation After Circulatory Death and Donation After Brain Death.

V van Suylen1, B Luijk2, R A S Hoek3, E A van de Graaf2, E A Verschuuren4, C Van De Wauwer1, J A Bekkers5, R C A Meijer6, W van der Bij4, M E Erasmus1.   

Abstract

The implementation of donation after circulatory death category 3 (DCD3) was one of the attempts to reduce the gap between supply and demand of donor lungs. In the Netherlands, the total number of potential lung donors was greatly increased by the availability of DCD3 lungs in addition to the initial standard use of donation after brain death (DBD) lungs. From the three lung transplant centers in the Netherlands, 130 DCD3 recipients were one-to-one nearest neighbor propensity score matched with 130 DBD recipients. The primary end points were primary graft dysfunction (PGD), posttransplant lung function, freedom from chronic lung allograft dysfunction (CLAD), and overall survival. PGD did not differ between the groups. Posttransplant lung function was comparable after bilateral lung transplantation, but seemed worse after DCD3 single lung transplantation. The incidence of CLAD (p = 0.17) nor the freedom from CLAD (p = 0.36) nor the overall survival (p = 0.40) were significantly different between both groups. The presented multicenter results are derived from a national context where one third of the lung transplantations are performed with DCD3 lungs. We conclude that the long-term outcome after lung transplantation with DCD3 donors is similar to that of DBD donors and that DCD3 donation can substantially enlarge the donor pool.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  bronchiolitis obliterans (BOS); clinical research/practice; donors and donation: donation after brain death (DBD); donors and donation: donation after circulatory death (DCD); lung (allograft) function/dysfunction; lung transplantation/pulmonology; organ procurement and allocation; organ transplantation in general; patient survival

Mesh:

Year:  2017        PMID: 28470870     DOI: 10.1111/ajt.14339

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  12 in total

Review 1.  Ex-vivo lung perfusion therapies: do they add value to organ donation?

Authors:  Amit Lyengar; Alexis Schiazza; Edward Cantu
Journal:  Curr Opin Organ Transplant       Date:  2022-06-01       Impact factor: 2.269

2.  A three-tier system for evaluation of organ procurement organizations' willingness to pursue and utilize nonideal donor lungs.

Authors:  Samantha E Halpern; Alec McConnell; Sarah B Peskoe; Vignesh Raman; Oliver K Jawitz; Ashley Y Choi; Megan L Neely; Scott M Palmer; Matthew G Hartwig
Journal:  Am J Transplant       Date:  2020-10-29       Impact factor: 8.086

Review 3.  Recent advances in lung transplantation.

Authors:  Keith C Meyer
Journal:  F1000Res       Date:  2018-10-23

4.  Ex Vivo Assessment of Porcine Donation After Circulatory Death Lungs That Undergo Increasing Warm Ischemia Times.

Authors:  Eric J Charles; J Hunter Mehaffey; Mary E Huerter; Ashish K Sharma; Mark H Stoler; Mark E Roeser; Dustin M Walters; Curtis G Tribble; Irving L Kron; Victor E Laubach
Journal:  Transplant Direct       Date:  2018-11-12

Review 5.  Complement Therapeutics in the Multi-Organ Donor: Do or Don't?

Authors:  Judith E van Zanden; Neeltina M Jager; Mohamed R Daha; Michiel E Erasmus; Henri G D Leuvenink; Marc A Seelen
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561

6.  Premortem anticoagulation timing and dose in donation after circulatory death: multicentre study of associations with graft function.

Authors:  Andreas H Kramer; Kerry Holliday; Sean Keenan; George Isac; Demetrius J Kutsogiannis; Norman M Kneteman; Peter Kim; Adrian Robertson; Peter W Nickerson; Lee Anne Tibbles
Journal:  Can J Surg       Date:  2022-07-28       Impact factor: 2.840

7.  Predictors of nonuse of donation after circulatory death lung allografts.

Authors:  Ashley Y Choi; Oliver K Jawitz; Vignesh Raman; Michael S Mulvihill; Samantha E Halpern; Yaron D Barac; Jacob A Klapper; Matthew G Hartwig
Journal:  J Thorac Cardiovasc Surg       Date:  2020-05-07       Impact factor: 5.209

8.  Lung transplantation using allografts with more than 8 hours of ischemic time: A single-institution experience.

Authors:  Samantha E Halpern; Sandra Au; Samuel J Kesseli; Madison K Krischak; Danae G Olaso; Brandi A Bottiger; John C Haney; Jacob A Klapper; Matthew G Hartwig
Journal:  J Heart Lung Transplant       Date:  2021-06-23       Impact factor: 10.247

9.  Aggressive pursuit and utilization of non-ideal donor lungs does not compromise post-lung transplant survival.

Authors:  Samantha E Halpern; Oliver K Jawitz; Vignesh Raman; Ashley Y Choi; John C Haney; Jacob A Klapper; Matthew G Hartwig
Journal:  Clin Transplant       Date:  2021-07-14       Impact factor: 3.456

10.  Donor Leukocyte Trafficking and Damage-associated Molecular Pattern Expression During Ex Vivo Lung Perfusion.

Authors:  Robert P Davis; John Yerxa; Qimeng Gao; Jared Gloria; Uwe Scheuermann; Mingqing Song; Min Zhang; William Parker; Jaewoo Lee; Matthew G Hartwig; Andrew S Barbas
Journal:  Transplant Direct       Date:  2020-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.